Please login to the form below

Not currently logged in
Email:
Password:

MPDL3280A

This page shows the latest MPDL3280A news and features for those working in and with pharma, biotech and healthcare.

Roche gets first approval for PD-L1 inhibitor Tecentriq

Roche gets first approval for PD-L1 inhibitor Tecentriq

Specifically, the FDA has approved atezolizumab (MPDL3280A) - which will be sold as Tecentriq - for people with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed during or after

Latest news

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Roche sees the potential to combine these therapies with other immunotherapies already in its oncology portfolio, such as MPDL3280A, which targets the PD-L1 receptor on cancer cells.  .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics